| The Lasercomb Restores Hair but Not Dignity
The Hairmax Lasercomb sounds like something ordered from the back of a 1970s comic book, but clinical tests suggest it's an effective remedy to baldness. Now approved by the FDA for promotion, embarrassed baldies no longer need order Rogaine by the boxload—they can simply zap their scalp with lasers. Or at least male baldies: as they noted in their offical forums, the etiology of hair loss is different between sexes, and they had to do a separate trial for the ladies, yet to be concluded. The combs resemble the security wands waved by airport check-in guards, except, of course, for the angry red glare of its laser array. Treatments last 10-15 minutes and should be performed thrice weekly, according to their site. It involves, as you might expect, comb-like movements over the head. The standard model has 9 lasers, the cheaper SE edition only 5.
FDA Approves Laser-Based Hair Comb To Combat Baldness
Washington, D.C. (AHN) - A Florida-based hair accessories company has reportedly received a federal approval on Thursday to sell a handheld laser device called Hairmax Lasercomb that claims thicker hair growth. The laser comb, which is manufactured by Lexington International LLC, has been seen to increase the numbers of thick hairs on the scalp by combining a low-level laser with a comb. When drawn through the hair, the laser touches the scalp to promote hair growth, the company officials' claim after 26-week clinical trials. According to AP reports, Hairmax Lasercomb is already sold on the Web for $545 and is the only drug-free product meant for home use in controlling hair loss that's won the approval of the Food and Drug Administration. Low Level Laser Therapy (LLLT) has been widely used in Europe for over thirty years in addition to being the subject of numerous studies with over 3,500 scientific papers published worldwide.
SkinMedica(R) Announces Commercial Launch of Desonate(TM ...
CARLSBAD, Calif., Feb. 12 /PRNewswire/ -- SkinMedica, Inc., a specialty pharmaceutical company focused on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and improve the appearance of skin, today announced the commercial availability of Desonate(TM) (desonide) Gel 0.05% for treatment of mild-to-moderate atopic dermatitis. Collaboratively developed by SkinMedica and Dow Pharmaceutical Sciences, Inc., Desonate is a low-potency topical steroid formulated in Dow's proprietary water-based Hydrogel vehicle. Desonate, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of atopic dermatitis in patients aged 3 months and older for up to four consecutive weeks, is an appropriate therapy for both pediatric and adult patients.
|
